Disease Models & Mechanisms (Aug 2015)

Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype

  • Val A. Fajardo,
  • Eric Bombardier,
  • Elliott McMillan,
  • Khanh Tran,
  • Brennan J. Wadsworth,
  • Daniel Gamu,
  • Andrew Hopf,
  • Chris Vigna,
  • Ian C. Smith,
  • Catherine Bellissimo,
  • Robin N. Michel,
  • Mark A. Tarnopolsky,
  • Joe Quadrilatero,
  • A. Russell Tupling

DOI
https://doi.org/10.1242/dmm.020859
Journal volume & issue
Vol. 8, no. 8
pp. 999 – 1009

Abstract

Read online

Centronuclear myopathy (CNM) is a congenital myopathy that is histopathologically characterized by centrally located nuclei, central aggregation of oxidative activity, and type I fiber predominance and hypotrophy. Here, we obtained commercially available mice overexpressing phospholamban (PlnOE), a well-known inhibitor of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs), in their slow-twitch type I skeletal muscle fibers to determine the effects on SERCA function. As expected with a 6- to 7-fold overexpression of phospholamban, SERCA dysfunction was evident in PlnOE muscles, with marked reductions in rates of Ca2+ uptake, maximal ATPase activity and the apparent affinity of SERCA for Ca2+. However, our most significant discovery was that the soleus and gluteus minimus muscles from the PlnOE mice displayed overt signs of myopathy: they histopathologically resembled human CNM, with centrally located nuclei, central aggregation of oxidative activity, type I fiber predominance and hypotrophy, progressive fibrosis and muscle weakness. This phenotype is associated with significant upregulation of muscle sarcolipin and dynamin 2, increased Ca2+-activated proteolysis, oxidative stress and protein nitrosylation. Moreover, in our assessment of muscle biopsies from three human CNM patients, we found a significant 53% reduction in SERCA activity and increases in both total and monomeric PLN content compared with five healthy subjects, thereby justifying future studies with more CNM patients. Altogether, our results suggest that the commercially available PlnOE mouse phenotypically resembles human CNM and could be used as a model to test potential mechanisms and therapeutic strategies. To date, there is no cure for CNM and our results suggest that targeting SERCA function, which has already been shown to be an effective therapeutic target for murine muscular dystrophy and human cardiomyopathy, might represent a novel therapeutic strategy to combat CNM.

Keywords